Regulation of vascular proteoglycan synthesis by metabolic factors associated with diabetes

Journal of Investigative Medicine

Volumn 55, Issue 1, 2007, Pages 18-25

  Wilson, Patricia ^a   Drennon, Katherine ^a   Tannock, Lisa R ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Atherosclerosis; Proteoglycans; Transforming growth factor

Indexed keywords

BIGLYCAN; FATTY ACID; GLUCOSE; INSULIN; PLATELET DERIVED GROWTH FACTOR; PROTEOGLYCAN; SULFATE; TRANSFORMING GROWTH FACTOR BETA1; VERSICAN;

ANIMAL CELL; ARTICLE; CARBOHYDRATE ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIUM CELL; METABOLIC PARAMETERS; MONKEY; NONHUMAN; PERITONEUM MACROPHAGE; PROTEIN EXPRESSION; PROTEOGLYCAN SYNTHESIS; SMOOTH MUSCLE FIBER; SWINE; VASCULAR SMOOTH MUSCLE; ANIMAL EXPERIMENT; ATHEROSCLEROSIS; CONFERENCE PAPER; CULTURE MEDIUM; MACROPHAGE; MOUSE; PROTEIN ANALYSIS; PROTEIN STRUCTURE; VASCULAR SMOOTH MUSCLE CELL;

EID: 34047118053     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/6650.2007.05067     Document Type: Article

References (48)

1. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 2001;285:2486-97.
2. Mooradian AD. Cardiovascular disease in type 2 diabetes mellitus: current management guidelines. Arch Intern Med 2003;163:33-40.
3. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15:551-61.
4. Schwenke DC, Carew TE. Initiation of atherosclerotic lesions in cholesterol-fed rabbits. Arteriosclerosis 1989;9: 908-18.
5. Schwenke DC, Carew TE. Initiation of atherosclerotic lesions in cholesterol-fed rabbits. I. Focal increases in arterial LDL concentration precede development of fatty streak lesions. Arteriosclerosis 1989;9:895-907.
6. Skalen K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002;417:750-4.
7. Wight TN. The vascular extracellular matrix. In: Fuster V, Ross R, Topol EJ, editors. Atherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven; 1996. p. 421-40.
8. Camejo G, Fager G, Rosengren B, et al. Binding of low density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells. J Biol Chem 1993;268:14131-7.
9. Chang MY, Potter-Perigo S, Tsoi C, et al. Oxidized low density lipoproteins regulate synthesis of monkey aortic smooth muscle cell proteoglycans that have enhanced native low density lipoprotein binding properties. J Biol Chem 2000;275:4766-73.
10. Little PJ, Tannock L, Olin KL, et al. Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-beta1 exhibit increased binding to LDLs. Arterioscler Thromb Vasc Biol 2002;22: 55-60.
11. Sambandam T, Baker JR, Christner JE, Ekborg SL. Specificity of the low density lipoprotein-glycosaminoglycan interaction. Arterioscler Thromb 1991;11:561-8.
12. Tannock LR, Little PJ, Wight TN, Chait A. Arterial smooth muscle cell proteoglycans synthesized in the presence of glucosamine demonstrate reduced binding to LDL. J Lipid Res 2002;43:149-57.
13. Vijayagopal P, Subramaniam P. Effect of calcium channel blockers on proteoglycan synthesis by vascular smooth muscle cells and low density lipoprotein-proteoglycan interaction. Atherosclerosis 2001;157:353-60.
14. Wang Y, Oram JF. Unsaturated fatty acids inhibit cholesterol efflux from macrophages by increasing degradation of ATP-binding cassette transporter A1. J Biol Chem 2002;277:5692-7.
15. Toborek M, Lee YW, Kaiser S, Hennig B. Measurement of inflammatory properties of fatty acids in human endothelial cells. Methods Enzymol 2002;352:198-219.
16. Kunjathoor VV, Wilson DL, LeBoeuf RC. Increased atherosclerosis in streptozotocin-induced diabetic mice. J Clin Invest 1996;97:1767-73.
17. Schonherr E, Jarvelainen HT, Kinsella MG, et al. Platelet derived growth factor and transforming growth factor-beta1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells. Arterioscler Thromb 1993;13:1026-36.
18. Schonherr E, Jarvelainen HT, Sandell LJ, Wight TN. Effects of platelet-derived growth factor and transforming growth factor, beta1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells. J Biol Chem 1991;66:17640-7.
19. Nomura K, Tada H, Kuboki K, Inokuchi T. Transforming growth factor-beta-1 latency-associated peptide and soluble betaglycan prevent a glucose-induced increase in fibronectin production in cultured human mesangial cells. Nephron 2002;91:606-11.
20. Cao Z, Flanders KC, Bertolette D, et al. Levels of phosphoSmad2/3 are sensors of the interplay between effects of TGF-beta and retinoic acid on monocytic and granulocytic differentiation of HL-60 cells. Blood 2003;101:498-507.
21. Wahab NA, Harper K, Mason RM. Expression of extracellular matrix molecules in human mesangial cells in response to prolonged hyperglycaemia. Biochem J 1996; 316(Pt 3):985-92.
22. Zhu Y, Casado M, Vaulont S, Sharma K. Role of upstream stimulatory factors in regulation of renal transforming growth factor-beta1. Diabetes 2005;54:1976-84.
23. Olsson U, Bondjers G, Camejo G. Fatty acids modulate the composition of extracellular matrix in cultured human arterial smooth muscle cells by altering the expression of genes for proteoglycan core proteins. Diabetes 1999;48:616-22.
24. Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 1998;9:471-4.
25. Poczatek MH, Hugo C, Darley-Usmar V, Murphy-Ullrich JE. Glucose stimulation of transforming growth factor-beta bioactivity in mesangial cells is mediated by thrombospondin-1. Am J Pathol 2000;157:1353-63.
26. Flores L, Naf S, Hernaez R, et al. Transforming growth factor beta at clinical onset of type 1 diabetes mellitus. A pilot study. Diabet Med 2004;21:818-22.
27. Pfeiffer A, Middelberg-Bisping K, Drewes C, Schatz H. Elevated plasma levels of transforming growth factor-beta 1 in NIDDM. Diabetes Care 1996;19:1113-7.
28. Sharma K, Ziyadeh FN, Alzahabi B, et al. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 1997;46:854-9.
29. Grainger DJ. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 2004;24:399-404.
30. Lutgens E, Gijbels M, Smook M, et al. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol 2002;22:975-82.
31. Mallat Z, Gojova A, Marchiol-Fournigault C, et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 2001;89:930-4.
32. Border WA, Noble NA, Yamamoto T, et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992;360: 361-4.
33. Fukushima D, Butzow R, Hildebrand A, Ruoslahti E. Localization of transforming growth factor beta binding site in betaglycan. Comparison with small extracellular matrix proteoglycans. J Biol Chem 1993;268:22710-5.
34. Hildebrand A, Romaris M, Rasmussen LM, et al. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J 1994;302(Pt 2):527-34.
35. Huijun W, Long C, Zhigang Z, et al. Ex vivo transfer of the decorin gene into rat glomerulus via a mesangial cell vector suppressed extracellular matrix accumulation in experimental glomerulonephritis. Exp Mol Pathol 2005;78:17-24.
36. Kolb M, Margetts PJ, Sime PJ, Gauldie J. Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. Am J Physiol Lung Cell Mol Physiol 2001;280:L1327-34.
37. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 1990;346:281-4.
38. Mazany KD, Kuriakose G, Eichstetter I, et al. Genetic modification of arterial matrix in vivo substantially alters the development of early atherosclerosis: the decorin null mouse [abstract]. Circulation 2000;108:169.
39. Al Haj Zen A, Caligiuri G, Sainz J, et al. Decorin overexpression reduces atherosclerosis development in apolipoprotein E-deficient mice. Atherosclerosis 2005;187:31-9.
40. Cardoso L, Maurao PAS. Glycosaminoglycan fractions from human arteries presenting diverse susceptibilities to atherosclerosis have different binding affinities to plasma low density lipoprotein. Arterioscler Thromb 1994;14:115-24.
41. Stevens RL, Colombo M, Gonzales JJ, et al. The glycosaminoglycans of the human artery and their changes in atherosclerosis. J Clin Invest 1976;58:470-81.
42. Heickendorff L, Ledet T, Rasmussen LM. Glycosaminoglycans in the human aorta in diabetes mellitus: a study of tunica media from areas with and without atherosclerotic plaque. Diabetologia 1994;37:286-92.
43. Wasty F, Alavi MZ, Moore S. Distribution of glycosaminoglycans in the intima of human aortas: changes in atherosclerosis and diabetes mellitus. Diabetologia 1993;36: 316-22.
44. O'Brien KD, Lewis K, Fischer JW, et al. Smooth muscle cell biglycan overexpression results in increased lipoprotein retention on extracellular matrix: implications for the retention of lipoproteins in atherosclerosis. Atherosclerosis 2004;177:29-35.
45. O'Brien KD, Olin KL, Alpers CE, et al. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: co-localization of biglycan with apolipoproteins. Circulation 1998;98:519-27.
46. Wight T. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol 2002;14:617.
47. Wight TN, Lara S, Riessen R, et al. Selective deposits of versican in the extracellular matrix of restenotic lesions from human peripheral arteries. Am J Pathol 1997;151:963-73.
48. Schonherr E, Kinsella MG, Wight TN. Genistein selectively inhibits platelet-derived growth factor-stimulated versican biosynthesis in monkey arterial smooth muscle cells. Arch Biochem Biophys 1997;339:353-61.